Kornimate/medical-research-clean huggingface dataset:
remifentanil and local anesthesia compared with local anesthesia for the insertion of central venous catheters

Conditions: Local Anesthesia

Summary: at present, there is no reference protocol for central venous catheter (cvc) insertion assuring analgesia, anxiolysis and safety. medical teams use various levels of analgesia and anesthesia to realize this gesture, from single local anesthesia to general anesthesia. remifentanil has been shown to decrease pain scores for insertion and removal of long-term central venous access. remifentanil is also often employed for pediatric or labor analgesia for short acts as procedural sedation.


Eligibility criteria:
inclusion criteria: * more than 18 years old * eligible for cvc insertion exclusion criteria: * pregnancy * patients who can't give their consent * contra-indications to remifentanil infusion

Keywords: central venous catheter remifentanil local anesthesia pain
cardiofocus vs. contact force guided pulmonary vein isolation in paroxysmal atrial fibrillation

Conditions: Paroxysmal Atrial Fibrillation

Summary: the aim of the study is to compare the acute procedure and safety outcomes as well as long term clinical outcomes of 2 groups of patients treated with the heartlight® endoscopically guided laser ablation (egla) or a commercially available contact force sensing irrigated radiofrequency (rf) ablation catheter plus, at the operator's discretion, 3d electroanatomical mapping (eam) for the treatment of paroxysmal atrial fibrillation (paf).


Eligibility criteria:
inclusion criteria: * patient must not have undergone a previous ablation for the treatment of paf * af type - diagnosed with symptomatic paroxysmal atrial fibrillation (paf) where paf is defined as recurrent (two or more) episodes of af that terminate spontaneously in less than seven days, usually less than 48 hours exclusion criteria: * atrial fibrillation secondary to a reversible cause or of non-cardiac origin * diagnosed with persistent atrial fibrillation defined as recurrent episodes lasting more than 7 and less than 365 days * more than 4 electrical cardioversions in the year prior to enrollment but not including cardioversions performed within 48 hours of arrhythmia onset * documented left atrial thrombus on imaging * cannot be removed from anti-arrhythmic drugs for other reasons than atrial fibrillation * new york heart association (nyha) functional class iii or class iv heart failure * left ventricular ejection fraction \< 30% * left atrial size \> 55 mm as measured in the parasternal antero-posterior view * myocardial infarction within 60 days prior to enrolment * woman of childbearing potential who is pregnant, lactating or not using adequate birth control
study to evaluate the safety and efficacy of two adalimumab dosing regimens in subjects with moderate to severe ulcerative colitis

Conditions: Ulcerative Colitis (UC)

Summary: to evaluate safety and efficacy of two adalimumab dosing regimens for induction and maintenance (standard and higher dosing) in achieving clinical remission in subjects with moderately to severely active ulcerative colitis.


Eligibility criteria:
inclusion criteria: * diagnosis of ulcerative colitis (uc) for at least 90 days, confirmed by endoscopy during screening period. * active uc with mayo score of 6 to 12 points and endoscopy subscore of 2 to 3 despite concurrent or prior treatment with a full and adequate course, in the opinion of the investigator, with oral corticosteroids or immunosuppressants or both. mayo score is confirmed by central reader. exclusion criteria: * subject with crohn's disease (cd) or indeterminate colitis (ic). * current diagnosis of fulminant colitis and/or toxic megacolon. * subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy. * chronic recurring infections or active tuberculosis (tb).

Keywords: ulcerative colitis
clinical observation of titration induction and convention induction of propofol

Conditions: Propofol Overdose of Undetermined Intent

Summary: as we know propofol is popular use in the anesthesia induction with kilogram and it always cause hypotension. so we compare haemodynamic changes and drug consumption between propofol titrated administration and traditional administration for anesthesia induction.

groupⅰreceived propofol 2 mg/kg intravenously by fresenius pump at the speed of 250 mg/min, groupⅱreceived propofol intravenously by fresenius pump at the speed of 1 mg/kg/min, and observe's assessment of alertness and sedation(oaa/s) scale of the patients was titrated to 1, then changed to a maintenance dose

Eligibility criteria:
inclusion criteria: * patients with american society of anesthesiologists(asa)ⅰor ⅱ and aged 18-60 yr, who were scheduled for general anesthesia. exclusion criteria: * hypertension, severe heart,pulmonary,brain，liver and renal dysfunction; excess obesity , predicted difficult intubation,hearing obstacles;. allergic to propofol or its fat emulsion;addictive to sedative and other drugs.
subcutaneous immunotherapy treatment for patients with hypersensitivity to grass pollen

Conditions: Seasonal Allergic Rhinitis

Summary: the objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerised with glutaraldehyde)of the subcutaneous injection of phleum pratense pollen in the treatment of patients affected by allergic rhinitis/ rhinoconjunctivitis ( with or without episodic asthma) induced by hypersensitivity to grass pollen, evaluating the score regarding symptoms and consumption of the medication.

immunotherapy is a specific treatment for allergic diseases. unlike conventional pharmacological treatment, immunotherapy is the only treatment that could modify the natural course of allergic disease. this is a prospective double-blind placebo controlled study with two arms of treatment in an up-dosing cluster regimen for 4 weeks.

Eligibility criteria:
inclusion criteria: * informed consent, signed by the subject. * clinical history of moderate to severe rhinitis/rhinoconjunctivitis lasting for at least 2 consecutive years, with or without episodic asthma, caused by allergy to grass pollen. * patient of both gender aged from 18 up to 55 * symptoms that coincide with allergy to grass pollen * sensitivity to grass pollen, diagnosed through a positive skin reaction to phleum pratense: positive prick test and /or specific ige to p.pratense \>0,7ku/l patients included must be mono-sensitised or, in the case of poly-sensitisation, sensitivity to p.pratense pollen should be considered as the only relevant aspect of their condition from the clinical standpoint. * patients who are able to comply with the dose regime exclusion criteria: * patient with mild rhinitis/rhinoconjunctivitis * relevant sensitivity to another perennial allergen * use of immunotherapy during the last four years * treatment with b. blocking agents * patient suffering from some pathology in which adrenalin was contraindicated * subject suffers from a serious medical condition, which would interference the treatment and follow up of the subject in the study * subject suffers from autoimmune disease(thyroiditis, lupus, etc.) * conditions in which the patient can not offer full co-operation and significant psychiatric disorders. * intolerance to aspirin * pregnant women or with pregnancy risk and breast-feeding

Keywords: immunotherapy allergoid depigmented polymerized allergen-extract rhinoconjunctivitis
sleep, autonomic nervous system and cardiorespiratory capacity in autism spectrum disorders children (apautres)

Conditions: Autonomic Nervous System Diseases; Sleep

Summary: autism spectrum disorders (asd) is a neurodevelopmental disorder which involves social and behavioural impairments. autonomic dysfunctions and disturbed sleep were often associated to asd. the investigators proposed to explore the impact of physical activity on these disorders. in this context, it is necessary to characterize the cardiorespiratory capacities of asd children in order to promote physical activity for this population. to examine potential differences between asd and control children, some explorations were proposed: a maximal treadmill test, motor evaluation, and orthostatic test (for the evaluation of autonomic nervous system). an actimetry during one week (evaluation of physical activity and sleep) completed this study in order to specify sleep characteristic and established the possible link between physical activity sleep characteristics and physical fitness in asd children.


Eligibility criteria:
inclusion criteria: * children physically active * children with an intellectual quotient \>70 * for autism children a diagnosis of autism in accordance to dsmv exclusion criteria: * history of cardio-vascular disease * history of asthma or respiratory disease * behavior disorders. * medical treatment by neuroleptic or melatonin or antiepileptic

Keywords: autism spectrum disorder
ultrasound study by texturization as a predictor of pregnancy in oocyte donation programs

Conditions: Infertility

Summary: this study is focused on analysing the application of ultrasound scanning techniques as new biomarkers in reproductive medicine. those biomarkers are based on the analysis of ultrasound texture in different areas of uterine tissue, using 2d/3d ultrasound scanning. investigators will use the algorithm text® to analyse the ultrasound texture of the endometrium and myometrium. the aim of the project is to study if it is possible to obtain measurable, objective and reproducible data in healthy volunteers which can be used to predict pregnancy and determine the best moment to perform embryo transfer in assisted reproductive technology (art) cycles


Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 18 and 30 kg/m2 * not taking the contraceptive pill in a previous cycle * non-pregnant: beta human chorionic gonadotropin (hcg) test with negative result at the beginning of the study) * no previous history of inflammatory diseases, circulatory diseases, abdomen or pelvic diseases * physical gynecological exploration without pathological findings * gynecological ultrasound study of the uterus with a normal result exclusion criteria: * ultrasound studies with technical defects in image acquisition * simultaneous participation in other studies * previous participation in other study which can affect the results of the present study

Keywords: texturization pregnancy rate oocyte donation 2d ultrasound 3d ultrasound assisted reproductive technology (art)
study to develop a breath analyser to detect chronic kidney disease

Conditions: Kidney Diseases

Summary: measure trimethylamine oxide in the breath.

organic compounds such as trimethylamine oxide (tmao) accumulate in the blood of patients with kidney disease, and volatile compounds such as tmao can be detected in the breath. the investigators wish to develop a breath analyser to measure volatile compounds, such as tmao in the breath in patients with kidney disease.

Eligibility criteria:
inclusion criteria: * patients with kidney disease under the care of royal free hospital exclusion criteria: * patients unable to provide informed consent * patients unable to exhale into breath analyser
dietary supplementation with butyrate in individuals with liver steatosis and metabolic syndrome

Conditions: NAFLD; Metabolic Syndrome

Summary: this was a double-blind, randomized, placebo-controlled clinical study aiming to assess the effect of a food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin d3 on liver steatosis in individuals with nafld and metabolic syndrome


Eligibility criteria:
inclusion criteria: * 40-75 years of age * caucasian ethnicity * nafld * metabolic syndrome exclusion criteria: * acute and chronic gastrointestinal disorder not controlled by stable treatment since at least 3 months * serious or disabling diseases (e.g. severe organ failure, malignancy or dementia) * obesity (body mass index (bmi)\> 30 kg/m2) * type 1 and 2 diabetes * alcoholism * pregnancy and breastfeeding * any medical or surgical condition making complex or inconstant the adhesion to the study protocol
the effect of acyl-ghrelin on kidney function and blood pressure in healthy volunteers

Conditions: Renal Tubular Transport

Summary: ghrelin (growth hormone release inducer) is produced in the stomach. the active form of ghrelin is acyl-ghrelin. acyl-ghrelin stimulates the ghrelin receptors. ghrelin receptors are detected in the distal tubules in mice and animal studies have shown that ghrelin increases the absorption of sodium in the renal tubules. ghrelin infusion directly into the renal artery of rats increased sodium reabsorption in the distal nephron, presumably via the epithelial sodium channels (enac). the purpose of the study is to measure the acyl-ghrelin induced effects on gfr, tubular transport of sodium and water in different nephron segments and central and peripheral blood pressure in a randomized, cross-over, single-blind, placebo-controlled dose-response study.


Eligibility criteria:
inclusion criteria: * age 18-40 years, * bmi 18,5-30kg/m2, * women must use contraception. exclusion criteria: * tobacco smoking, * substance abuse, * consumption of more than 7 units of alcohol/week for women and more than 14 units/week for men, * medical treatment except for contraception, * pregnancy or nursing, * allergy to acyl-ghrelin, * significant clinical signs of heart-, lung-, liver-, kidney-, endocrine-, brain- or neoplastic disorders, * clinically significant abnormal findings in screening blood samples, * urine sample or ecg, * office blood pressure over 140/90 mmhg, * donation of blood within 1 month of the first day of investigation.
fetal lung volume and pulmonary artery resistance index measurement in term diabetic pregnancy

Conditions: Respiratory Distress Syndrome

Summary: the aim of this study is to determine cut-off values for fetal lung volume by vocal and pulmonary artery resistance index by pulsed doppler in fetuses of diabetic mothers, and correlate the results with postnatal respiratory distress of the term neonates.

research question: can the assessment of fetal lung volume by virtual organ computed-aided analysis (vocal) and pulmonary artery resistance index by pulsed doppler predict neonatal respiratory distress syndrome in term fetuses of diabetic mothers? research hypothesis: the assessment of fetal lung volume by vocal and pulmonary artery resistance index by pulsed doppler can predict neonatal respiratory distress syndrome in term fetuses of diabetic mothers.

Eligibility criteria:
inclusion criteria: -diabetic pregnant women 38 weeks gestation admitted for elective termination due to various obstetric indications exclusion criteria: 1. twins. 2. pregnancy complicated by medical disorders other than diabetes mellitus (hypertension, pre-eclampsia, cardiac disorders, thyroid disorders, anemia with pregnancy...etc). 3. autoimmune disorders. 4. congenital fetal anomalies. 5. macrosomia and intrauterine growth restriction (iugr). 6. intrauterine fetal death (iufd). 7. amniotic fluid index \ 20cm. 8. patients taking steroids within one week of measurement of lung volume.
inhaled corticosteroid replacement study - efficacy and safety of ro 27-2441 (test drug) in moderate persistent asthma

Conditions: Asthma

Summary: the primary objective of the study is to evaluate the anti-inflammatory action and safety of ro 27-2441 (study drug) in asthmatic patients currently taking inhaled corticosteroids. the research is being conducted at up to 40 clinical research sites in the us. study participants will have a number of visits to a research site over a 4-month period.


Eligibility criteria:
inclusion criteria: * persistent asthma for more than 1 year * currently receiving treatment with a stable dose of inhaled corticosteroids for more than 3 months * in good health as demonstrated by medical history and physical exam * negative urine pregnancy test * commitment to use two forms of effective contraception simultaneously throughout the study duration and for 1 month after discontinuing therapy exclusion criteria: * hospitalization for treatment of asthma and/or treatment with oral/injectable corticosteroids within 3 months before the start of the study * undergoing allergy shots unless on a stable maintenance dose for 3 months before the start of the study * history of chronic pulmonary diseases other than asthma * treatment of conditions other than asthma with oral corticosteroids within 1 month of the start of the study * current tobacco usage * smoking history of greater than 10 pack-year history of cigarette smoking (number of packs smoked per day times the number of years smoked) * history or evidence of drug or alcohol abuse * diagnosis or evidence of an infectious illness within one month of visit 1 * clinically significant diseases as assessed by the study doctor * participation in another clinical study with an experimental drug within one month of start of the study
screening for metabolic problems in mothers of children with autism and typically developing children

Conditions: Pregnancy; Autistic Disorder; Folic Acid Deficiency

Summary: the purpose of this research study is to screen for metabolic abnormalities that are maternal risk factors for having a child with autism.

the study will involve recruitment of 30 mothers of young children with asd (ages 3-5 years) and 30 mothers of non-asd children of similar age, respectively labelled asd-moms and non-asd-moms. in phase 1, the levels of certain folate-related and oxidative stress biomarkers (folate, vitamin b12, vitamin e, homocysteine, methylmalonic acid, urinary isoprostanes) and mthfr mutation analysis will be measured in all the mothers. the investigators expect that approximately 40-50% of the asd-mothers and approximately 5-10% of the non-asd-mothers will have abnormal homocysteine levels. in phase 2, for those mothers with abnormal homocysteine levels, the investigators will treat them with a standard prenatal supplement for 4 weeks, and re-measure their biomarkers. the investigators expect 75-100% of the non-asd mothers to respond, but only 25-50% of the asd-mothers to respond. in phase 3, for those mothers who did not respond to the standard prenatal supplement, the investigators will treat them with an optimized prenatal supplement for 4 weeks and remeasure their biomarkers. the investigators expect that 75-100% of the mothers of both groups will respond to this improved prenatal supplement.

Eligibility criteria:
mothers of children with autism (age 3-5) or typically-developing children (age 3-5) who are not currently taking prenatal vitamins/multivitamins.

Keywords: maternal health autistic disorder metabolism folic acid
china peace-prospective pci study

Conditions: Coronary Heart Disease

Summary: coronary heart disease (chd) pose a serious health threaten to population. pci, as a well-proved and booming measure in chd management, is invasive and of high cost, however the knowledge about the real-life pci use in china is limited. by consecutively recruiting pci patients in 30 geographically representative highest-rank hospitals, this study will examine various real-life factors, that may affect patients recovery after the procedure. practical guidelines, appropriateness criteria and quality evaluative system for pci will be established based on the findings, to improve patients outcomes in future finally.

cardiovascular disease (cvd) is a major concern in public health globally, as well as in china, and remarkable variations of resources available and health system performance have been noted. relatively limited information is available about how evidence-based therapies are incorporated appropriately into routine clinical practice. in addition, little information is available about the magnitude and quality of pci, which has developed rapidly during the past several decades. practical and applied knowledge from large unselected population is needed to guide practice and policy for quality improvement and cost reduction. this study will enroll patients undergoing pci after admission consecutively in 30 tertiary hospitals scattered all over china. at study entry, participants will be interviewed during their index hospitalization, to collect information about symptoms, functioning, quality of life, and medical care. demographic characteristics, medical history, clinical features, diagnostic tests, medications, procedures, and in-hospital outcomes of patients will be abstracted from medical records by well trained professional abstractors. and cag imaging will be reviewed by national and international expert panels. at 1 month, 6 month, and 12 month after discharge, participants will return to the clinic for follow up visits, a face-to-face interview will be conducted to get information about clinical events, symptoms, functioning, quality of life, and medical care during the recovery period. at 1-month and 12-month follow-up visit, blood and urine sample will be collected. participants' blood samples will be stored for future biologic and genetic studies. this study will examine various real-life factors that may affect patients recovery after pci, including patients' characteristics and treatment measures. practical guidelines, quality evaluative system, and appropriateness criteria will be established based on the findings, to improve patients outcomes in future finally.

Eligibility criteria:
inclusion criteria: * hospitalized patients undergoing a percutaneous coronary intervention (pci) with stents implantation for coronary lesions. exclusion criteria: * previously enrolled in the peace study
bone loss in melanoma survivors receiving immunotherapy

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8

Summary: this study investigates the bone-related side effects caused by immunotherapy drugs such as nivolumab and pembrolizumab in patients with melanoma. nivolumab and pembrolizumab are immunotherapy drugs (drugs that boost your immune system) used to prevent cancer from coming back in patients with melanoma. specifically, researchers want to learn if there is any relationship between receiving immunotherapy and bone density (thickness) measured by a dual-energy x-ray absorptiometry (dxa) scan or bone turnover markers (which indicate levels of bone loss) found in the blood. this study may provide researchers with more information on bone loss and may help prevent bone loss in future patients.

primary objectives: i. characterize the effects of adjuvant immune checkpoint inhibitor (ici) therapy (nivolumab or pembrolizumab) on measures of bone health, including bone density and bone turnover markers, in a prospectively recruited cohort of 40 adult patients (\>= 40 years) with melanoma diagnoses seen at md anderson cancer center. ii. identify associations of baseline demographic, clinical, and general bone loss risk factors (e.g., age, corticosteroid use) and tumor characteristics with bone loss in the same cohort. outline: patients undergo collection of blood samples after starting immunotherapy and then at 6 and 12 months. patients also undergo dxa scan over 5-10 minutes after starting immunotherapy and at 12 months.

Eligibility criteria:
inclusion criteria: * stage iii or iv melanoma with no evidence of disease following resection according to the 2009 american joint committee on cancer classification criteria * no prior history of osteoporosis or fractures as per medical record review and patient history * scheduled to begin receiving adjuvant ici therapy (nivolumab or pembrolizumab) irrespective of dose or setting * plan to continue care, including ici infusions, at md anderson